

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
16 June 2005 (16.06.2005)

PCT

(10) International Publication Number  
**WO 2005/054502 A1**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68,  
C07H 21/00

(21) International Application Number:  
PCT/EP2004/013627

(22) International Filing Date: 1 December 2004 (01.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
03027754.5 2 December 2003 (02.12.2003) EP

KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for the following designa-  
tions* AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW,  
BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC,  
EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,  
IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,  
MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ,  
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,  
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA,  
ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,  
NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,  
BE, BG, CH, CY, CZ, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR),  
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG)
- *of inventorship (Rule 4.17(iv)) for US only*

**Published:**

- *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(71) Applicant (*for DE only*): ROCHE DIAGNOSTICS  
GMBH [DE/DE]; Sandhofer Strasse 116, 68305  
Mannheim (DE).

(71) Applicant (*for all designated States except DE, US*):  
F.HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacher-  
strasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BIRKNER, Chris-  
tian [DE/DE]; Willingstrasse 9, 82449 Uffing (DE).  
MARKERT-HAHN, Christine [DE/DE]; Saelweiher-  
strasse 54, 82377 Penzberg (DE). VON DER ELTZ,  
Herbert [DE/DE]; In der Au 21, 82362 Weilheim (DE).

(74) Common Representative: BURGER, Alexander; Roche  
Diagnostics GmbH, Patent Department, 82377 Penzberg  
(DE).

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

(54) Title: IMPROVED METHOD FOR BISULFITE TREATMENT

(57) Abstract: The invention is related to the detection of a methylated cytosine in a nucleic acid wherein guanidinium hydrogen sulfite is used for the preparation of a solution containing guanidinium ions and sulfite ions and subsequent modification of the nucleic acid. Thereby, a non-methylated cytosine is converted to uracil. The invention further discloses uses of guanidinium hydrogen sulfite and kits containing it.

WO 2005/054502 A1

## Improved method for bisulfite treatment

### Field of the invention

The invention is related to the detection of a methylated cytosine in a nucleic acid  
5 wherein guanidinium hydrogen sulfite is used for the preparation of a solution  
containing guanidinium ions and sulfite ions and subsequent modification of the  
nucleic acid. Thereby, a non-methylated cytosine is converted to uracil. The  
invention further discloses uses of guanidinium hydrogen sulfite and kits  
containing it.

### 10 Background of the invention

Genes constitute only a small proportion of the total mammalian genome, and the  
precise control of their expression in the presence of an overwhelming background  
of noncoding deoxyribonucleic acid (DNA) presents a substantial problem for  
their regulation. Noncoding DNA, containing introns, repetitive elements, and  
15 potentially active transposable elements requires effective mechanisms for its long  
term silencing. Mammals appear to have taken advantage of the possibilities  
afforded by cytosine methylation to provide a heritable mechanism for altering  
DNA-protein interactions to assist in such silencing. DNA methylation is essential  
for the development of mammals; and plays a potential role during aging and  
20 cancer. The involvement of methylation in the regulation of gene expression and as  
an epigenetic modification marking imprinted genes is well established. In  
mammals, methylation occurs only at cytosine residues and more specifically only  
on cytosine residues adjacent to a guanosine residue, i.e. at the sequence CG. The  
detection and mapping of DNA methylation sites are essential steps towards  
25 understanding the molecular signals which indicate whether a given sequence is  
methylated.

This is currently accomplished by the so-called bisulfite method described by  
Frommer, M., et al., Proc. Natl. Acad. Sci. USA 89 (1992) 1827-1831) for the  
detection of 5-methyl-cytosines. The bisulfite method of mapping 5-methylcytosine  
30 uses the effect that sodium hydrogen sulfite reacts with cytosine but not or only  
poorly with 5-methyl-cytosine. Cytosine reacts with bisulfite to form a sulfonated  
cytosine reaction intermediate being prone to deamination resulting in a sulfonated  
uracil which can be desulfonated to uracil under alkaline conditions. It is common

knowledge that uracil has the base pairing behavior of thymine different to the educt cytosine whereas 5-methylcytosine has the base pairing behavior of cytosine. This makes the discrimination of methylated or non-methylated cytosines possible by e.g. bisulfite genomic sequencing (Grigg, G., and Clark, S., Bioessays 16 (1994) 431-436; Grigg, G.W., DNA Seq. 6 (1996) 189-198) or methylation specific PCR (MSP) disclosed in US 5,786,146.

There are various documents addressing specific aspects of the bisulfite reaction (Benyajati, C., et al., Nucleic Acids Res. 8 (1980) 5649-5667) make general investigations to the bisulfite modification of 5-methyl-deoxycytosine and deoxycytosine (Olek, A., et al., Nucleic Acids Res. 24 (1996) 5064-5066) disclose a method for bisulfite base sequencing whereby bisulfite treatment and subsequent PCR steps are performed on material embedded in agarose beads. In the bisulfite method as disclosed by Clark, S. J., et al., Nucleic Acids Res. 22 (1994) 2990-2997, the sample is desalted after deamination.

Raizis, A.M., et al., Anal. Biochem. 226 (1995) 161-166 disclose a bisulfite method of 5-methylcytosine mapping that minimizes template degradation. They investigate the influence of pH, temperature and time of reaction. Similar investigations have been made by Grunau, C., et al., Nucleic Acids Res. 29 (2001) E65-5 or Warnecke, P.M., et al., Methods 27 (2002) 101-107. Different additional components in the bisulfite mixture are disclosed by WO 01/98528 or by Paulin, R., et al., Nucleic Acids Res. 26 (1998) 5009-5010. An additional bisulfite step after bisulfite treatment and PCR is disclosed in WO 02/31186. Komiyama, M., and Oshima, S., Tetrahedron Letters 35 (1994) 8185-8188) investigate the catalysis of bisulfite-induced deamination of cytosine in oligodeoxyribonucleotides.

Kits for performing bisulfite treatments are commercially available from Intergen, distributed by Serologicals Corporation, Norcross, GA, USA, e.g. CpGenome™ DNA modification kit.

A variation of the bisulfite genomic sequencing method is disclosed by Feil, R., et al., Nucleic Acids Res. 22 (1994) 695-696, whereby the genomic DNA is bound to glass beads after deamination and washed. After elution the nucleic acid is desulfonated. It is known that nucleic acids can be isolated by the use of their binding behavior to glass surfaces, e.g. adsorption to silica gel or diatomic earths,

adsorption to magnetic glass particles (MGPs) or organo silane particles under chaotropic conditions. Extraction using solid phases usually contains the steps of adding the solution with the nucleic acids to the solid phase under conditions allowing binding of the substance of interest to the solid phase, removal of the remainder of the solution from the solid phase bound nucleic acids and subsequent release of the nucleic acids from the solid phase into a liquid eluate (sometimes called elution). The result of the such process is usually a solution containing the substance of interest in dissolved state.

Guanidinium hydrogen sulfite is known from various documents. US 2,437,965 discloses a method for relaxing keratinous fibers using guanidinium hydrogen sulfite. US 2,654,678 discloses the antistatic treatment of shaped articles using guanidinium salts. US 4,246,285 discloses skin conditioning compositions containing guanidine inorganic salts. DE19527313 discloses guanidine derivatives and cosmetic articles containing them.

All prior art methods for the bisulfite treatment have disadvantages. Therefore, the problem to be solved by the present invention was to provide a method wherein guanidinium hydrogen sulfite is used.

#### Summary of the invention

The invention is related to a method for the conversion of a cytosine base in a nucleic acid to an uracil base comprising the steps of

- a) providing a solution that contains a nucleic acid,
- b) providing guanidinium hydrogen sulfite and preparing a solution comprising guanidinium and sulfite ions,
- c) mixing the solutions from step a) and b)
- d) incubating the solution obtained in step c) containing the nucleic acid and guanidinium and sulfite ions whereby the nucleic acid is deaminated,
- e) incubating the deaminated nucleic acid under alkaline conditions whereby the deaminated nucleic acid is desulfonated,
- f) isolating the deaminated nucleic acid.

30

In a further embodiment of the invention, guanidinium hydrogen sulfite is used for chemically modifying a nucleic acid, particularly in a method wherein a cytosine

base in a nucleic acid is converted to an uracil base. In another embodiment of the invention, guanidinium hydrogen sulfite is used to prepare a solution comprising guanidinium and sulfite ions, particularly the solution is used for converting a cytosine base in a nucleic acid to an uracil base.

- 5 In another embodiment of the invention, a kit containing guanidinium hydrogen sulfite is provided and uses of the kit according to the invention for a reaction wherein a cytosine base in a nucleic acid is converted to an uracil base in the presence of bisulfite ions.

- According to the invention the term a "bisulfite reaction", "bisulfite treatment" or  
10 "bisulfite method" shall mean a reaction for the conversion of a cytosine base, in particular cytosine bases, in a nucleic acid to an uracil base, or bases, preferably in the presence of bisulfite ions whereby preferably 5-methyl-cytosine bases are not significantly converted. This reaction for the detection of methylated cytosines is described in detail by Frommer et al., supra and Grigg and Clark, supra. The  
15 bisulfite reaction contains a deamination step and a desulfonation step which can be conducted separately or simultaneously (see Figure 1; Grigg and Clark, supra). The statement that 5-methyl-cytosine bases are not significantly converted shall only take the fact into account that it cannot be excluded that a small percentage of 5-methyl-cytosine bases is converted to uracil although it is intended to convert  
20 only and exclusively the (non-methylated) cytosine bases (Frommer et al., supra).

#### Detailed description of the invention

The invention is related to a method for the conversion of a cytosine base in a nucleic acid to an uracil base comprising the steps of

- a) providing a solution, preferably a sample, that contains a nucleic acid,  
25 b) providing guanidinium hydrogen sulfite and preparing a solution comprising guanidinium and sulfite ions,  
c) mixing the solutions from step a) and b) or preferably the sample from step a) and the solution from step b),  
d) incubating the solution obtained in step c) containing the nucleic acid and  
30 guanidinium and sulfite ions whereby the nucleic acid is deaminated,  
e) incubating the deaminated nucleic acid under alkaline conditions whereby the deaminated nucleic acid is desulfonated,

f) isolating the deaminated nucleic acid.

Guanidinium hydrogen sulfite is a salt and used in solid form, i.e. it should be primarily in dry form and not contain water although minor amounts of water, including crystal water may be present. Guanidinium hydrogen sulfite may be produced as described in the invention (see Example 1) or as described in US 2,437,965, US 2,654,678, US 4,246,285 or DE 19527313.

The preparation of the solution comprising guanidinium and sulfite ions is accomplished by methods known to the expert skilled in the art, particularly by combining water or a buffered solution and the guanidinium hydrogen sulfite and mechanically agitation by e.g. shaking, stirring, pipetting the solution up and down or any other suitable means known to the expert skilled in the art. As said above, the guanidinium hydrogen sulfite may also be dissolved in a buffered solution which may be an aqueous buffer, may contain further substances as organic substances, salts and buffering constituents known to the expert in the field as phosphate, Tris, HEPES or other suitable buffers.

The expert skilled in the art knows how to perform the bisulfite reaction, e.g. by referring to Frommer et al., supra or Grigg and Clark, supra who disclose the principal parameters of the bisulfite reaction. From Grunau et al., supra, it is known to the expert in the field what variations of the bisulfite method are possible. The influence of incubation time and temperature on deamination efficiency and parameters affecting DNA degradation is disclosed. In summary, in the deamination step a buffer containing bisulfite ions and chaotropic agents and optionally further reagents as an alcohol or stabilizers as hydroquinone are employed and the pH is in the acidic range. The concentration of bisulfite is between 0.1 to 6 M bisulfite, preferably 1 M to 5.5 M, the concentration of the chaotropic agent is between 1 to 8 M, whereby in general preferably guanidinium salts are employed but guanidinium hydrogen sulfite according to the invention as described herein, the pH is in the acidic range, preferably between 4.5 to 6.5, the temperature is between 0 °C to 90 °C, preferably between room temperature (25 °C) to 90 °C, and the reaction time is between 30 min to 24 hours or 48 hours or even longer, but preferably between 1 hour to 24 hours. The desulfonation step is performed by adding an alkaline solution or buffer as e.g. a solution only containing a hydroxide, e.g. sodium hydroxide, or a solution containing ethanol,

sodium chloride and sodium hydroxide (e.g. 38% EtOH, 100 mM NaCl, 200 mM NaOH) and incubating at room temperature or elevated temperatures for several min, preferably 5 min to 60 min.

Therefore, in an embodiment of the invention, in the method according to the invention, the concentration of guanidinium ions and sulfite ions is 0,1 to 8 M, preferably 2 to 8 M. In an embodiment of the invention, the pH of the solutions in step b) and c) of the method according to the invention is in the acidic range, preferably between 4.5 to 6.5. In an embodiment of the method according to the invention, the incubation temperature in step d) and e) of the method according to the invention is between 0 °C to 90 °C, preferably between 18 °C to 90 °C. In an embodiment of the method according to the invention, the incubation time in step d) is between 30 min to 48 hours, preferably 24 hours. In an embodiment of the invention, the step e) in the method according to the invention is performed by adding an alkaline solution or buffer, preferably a solution containing a hydroxide, preferably sodium hydroxide, or a solution containing ethanol, sodium chloride and sodium hydroxide, preferably a solution containing 38% (volume/volume) ethanol, 100 mM NaCl, 200 mM NaOH. In an embodiment of the invention, in the method according to the invention, the incubation temperature in step e) is between 0 °C to 90 °C, preferably between 18 °C to 90 °C. The incubation time in step e) of the method according to the invention is between 5 min to 60 min. In another embodiment of the invention, the incubation parameters as described in EP03001854.3 may be used, wherein the nucleic acid is incubated in a solution for a time period of 1.5 to 3.5 hours at a temperature between 70 and 90 °C, whereby the concentration of bisulfite in the solution is between 3 M and 6.25 M and whereby the pH value of the solution is between 5.0 and 6.0 whereby the nucleic acid is deaminated.

Desalting of the nucleic acid can be performed using magnetic glass particles as described in WO96/41811 or desulfonation and/ or desalting can be performed as described in EP 1 394 172.

In general, the method of the invention can be performed on solid surfaces as described in EP 1 394 172 or under the special conditions as described in EP 1 443 052.

In an embodiment of the invention, the nucleic acid is desoxyribonucleic acid (DNA), in particular genomic DNA or nucleic acid, i.e. the DNA or nucleic acid which is found in the organism's genome and is passed on to offspring as information necessary for survival. The phrase is used to distinguish between other  
5 types of DNA, such as found within plasmids. The source of the nucleic acid may be eukaryotic or prokaryotic, preferably from vertebrates, particularly from mammals, most preferred from animals or humans.

The solution that contains a nucleic acid is preferably a sample that contains a nucleic acid. Other compounds may be present but it is preferred that the solution  
10 containing the nucleic acid is as pure as possible. In another embodiment, the solution contains other insoluble components, i.e. it is a suspension preferably containing material comprising glass as e.g. magnetic glass particles as described in EP 1 394 172. In an embodiment of the invention the solution or the sample containing the nucleic acid is obtained from a biological sample using e.g. solid  
15 phases (see e.g. WO96/41811 or WO01/37291 or the MagNAPure® System available from Roche Diagnostics, Mannheim Germany) or other methods known to the expert in the field (see e.g. Sambrook et al.: Molecular Cloning, A Laboratory Manual, 2nd Addition, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY and Ausubel et al.: Current Protocols in Molecular Biology 1987, J.  
20 Wiley and Sons, NY or commercial DNA isolation kits available e.g. from Qiagen, Hilden Germany). The biological sample comprises cells from multicellular organisms as e.g. human and animal cells such as Leucocytes, and immunologically active low and high molecular chemical compounds such as haptens, antigens, antibodies and nucleic acids, blood plasma, cerebral fluid, sputum, stool, biopsy  
25 specimens, bone marrow, oral rinses, blood serum, tissues, urine or mixtures thereof. In a preferred embodiment of the invention the biological sample is a fluid from the human or animal body. The biological sample may be blood, blood plasma, blood serum or urine. The biological sample comprising the nucleic acid is lysed to create a mixture of biological compounds comprising nucleic acids and  
30 other components. Procedures for lysing biological samples are known by the expert and can be chemical, enzymatic or physical in nature. A combination of these procedures is applicable as well. For instance, lysis can be performed using ultrasound, high pressure, shear forces, alkali, detergents or chaotropic saline solutions, or proteases or lipases. For the lysis procedure to obtain nucleic acids,  
35 special reference is made to Sambrook et al.: Molecular Cloning, A Laboratory



Manual, 2nd Addition, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY and Ausubel et al.: Current Protocols in Molecular Biology 1987, J. Wiley and Sons, NY. Then the nucleic acids are isolated from the lysis mixture using the methods and solid phases according to the invention and can then be  
5 subjected to the methods according to the invention, i.e. the bisulfite treatment according to the invention. Chaotropic agents are also used to lyse cells to prepare a mixture between nucleic acids and other biological substances (see e.g. Sambrook et al. (1989) or EP 0 389 063). Afterwards the material comprising glass or silica may be added and a purification effect results from the behavior of DNA or RNA to  
10 bind to material with a glass surface under these conditions i.e. in the presence of certain concentrations of a chaotropic agent, higher concentrations of organic solvents or under acidic conditions. Alternative methods may be used as well.

In another embodiment of the invention, a method is provided for the conversion of a cytosine base in a nucleic acid to an uracil base comprising the steps of

- 15 a) providing guanidinium hydrogen sulfite and preparing a solution comprising guanidinium and sulfite ions,
- b) mixing the solution from step a) with a solution, preferably a sample, containing a nucleic acid,
- c) incubating the solution obtained in step b) containing the nucleic acid and  
20 guanidinium and sulfite ions whereby the nucleic acid is deaminated,
- d) incubating the deaminated nucleic acid under alkaline conditions whereby the deaminated nucleic acid is desulfonated,
- e) isolating the deaminated nucleic acid.

25 After the steps of the method according to the invention, further steps may be performed. In a preferred embodiment of the invention, the nucleic acid is amplified with the polymerase chain reaction (PCR; EP 0 201 184, EP-A-0 200 362, US 4,683,202). The amplification method may also be the ligase Chain Reaction (LCR, Wu, D.Y., and Wallace, R.B., Genomics 4 (1989) 560-569 and Barany, F.,  
30 Proc. Natl. Acad. Sci. USA 88 (1991) 189-193; Polymerase Ligase Chain Reaction (Barany, F., PCR Methods Appl. 1 (1991) 5-16); Gap-LCR (PCT Patent Publication No. WO 90/01069); Repair Chain Reaction (European Patent Publication No. EP 439,182 A2), 3SR (Kwoh, D.Y., et al., Proc. Natl. Acad. Sci. USA 86 (1989) 1173-1177; Guatelli, J.C., et al., Proc. Natl. Acad. Sci. USA 87 (1990) 1874-1878; PCT

- Patent Publication No. WO 92/0880A), and NASBA (U.S. Pat. No. US 5,130,238). Further, there are strand displacement amplification (SDA), transcription mediated amplification (TMA), and Q $\beta$ -amplification (for a review see e.g. Whelen, A.C., and Persing, D.H., *Annu. Rev. Microbiol.* 50 (1996) 349-373; Abramson, R.D., and Myers, T.W., *Curr. Opin. Biotechnol.* 4 (1993) 41-47). Particularly preferred amplification methods according to the invention are the methylation specific PCR method (MSP) disclosed in US 5,786,146 which combines bisulfite treatment and allele-specific PCR (see e.g. US 5,137,806, US 5,595,890, US 5,639,611). The bisulfite treatment may be performed according to the invention.
- 10 In a preferred embodiment, the method may further comprise the step of detecting the amplified nucleic acid. The amplified nucleic acid may be determined or detected by standard analytical methods known to the person skilled in the art and described e.g. in Sambrook, et al., *Molecular Cloning*, Cold Spring Harbor University Press (1989), Lottspeich and Zorbas, in "Bioanalytik" (1998), Eds. L. a. Zorbas, Spektrum Akademischer Verlag, Heidelberg, Berlin, Germany, or in Ausubel, F., et al., in "Current protocols in molecular biology" (1994), Eds. F. Ausubel, R. Brent and K. R.E., Wiley & Sons Verlag, New York. There may be also further purification steps before the target nucleic acid is detected e.g. a precipitation step. The detection methods may include but are not limited to the
- 20 binding or intercalating of specific dyes as ethidium bromide which intercalates into the double-stranded DNA and changes its fluorescence thereafter. The purified nucleic acids may also be separated by electrophoretic methods optionally after a restriction digest and visualized thereafter. There are also probe-based assays which exploit the oligonucleotide hybridisation to specific sequences and subsequent
- 25 detection of the hybrid. It is also possible to sequence the target nucleic acid after further steps known to the expert in the field. Other methods apply a diversity of nucleic acid sequences to a silicon chip to which specific probes are bound and yield a signal when a complementary sequences bind.
- In a particularly preferred embodiment of the invention, the nucleic acid is detected
- 30 by measuring the intensity of fluorescence light during amplification. This method entails the monitoring of real time fluorescence. A particularly preferred method exploiting simultaneous amplification and detection by measuring the intensity of fluorescent light is the TaqMan® method disclosed in WO 92/02638 and the corresponding US patents US 5,210,015, US 5,804,375, US 5,487,972. This method

exploits the exonuclease activity of a polymerase to generate a signal. In detail, the nucleic acid is detected by a process comprising contacting the sample with an oligonucleotide containing a sequence complementary to a region of the target nucleic acid and a labeled oligonucleotide containing a sequence complementary to a second region of the same target nucleic acid strand, but not including the nucleic acid sequence defined by the first oligonucleotide, to create a mixture of duplexes during hybridization conditions, wherein the duplexes comprise the target nucleic acid annealed to the first oligonucleotide and to the labeled oligonucleotide such that the 3'-end of the first oligonucleotide is adjacent to the 5'-end of the labeled oligonucleotide. Then this mixture is treated with a template-dependent nucleic acid polymerase having a 5' to 3' nuclease activity under conditions sufficient to permit the 5' to 3' nuclease activity of the polymerase to cleave the annealed, labeled oligonucleotide and release labeled fragments. The signal generated by the hydrolysis of the labeled oligonucleotide is detected and/ or measured. TaqMan® technology eliminates the need for a solid phase bound reaction complex to be formed and made detectable. In more general terms, the amplification and/ or detection reaction of the method according to the invention is a homogeneous solution-phase assay. Further preferred method are the formats used in the LightCycler® instrument (see e.g. US 6,174,670). Particularly preferred is the use of bisulfite treatment, amplification with or without methylation specific primers in the presence of a methylation-specific probe and real-time fluorescence detection as described in US 6,331,393.

In a preferred embodiment of the present invention, the method is automated, i.e. the method carries out an automatable process as e.g. described in WO 99/16781. Automatable process means that the steps of the process are suitable to be carried out with an apparatus or machine capable of operating with little or no external control or influence by a human being. Automated method means that the steps of the automatable method are carried out with an apparatus or machine capable of operating with little or no external control or influence by a human being. Only the preparation steps for the method may have to be done by hand, e.g. the storage containers have to be filled up and put into place, the choice of the samples has to be done by a human being and further steps known to the expert in the field, e.g. the operation of the controlling computer. The apparatus or machine may e.g. add automatically liquids, mix the samples or carry out incubation steps at specific temperatures. Typically, such a machine or apparatus is a robot controlled by a

computer which carries out a program in which the single steps and commands are specified. In a preferred embodiment of the invention, the method is in a high-throughput format, i.e. the automated methods is carried out in a high-throughput format which means that the methods and the used machine or apparatus are  
5 optimized for a high-throughput of samples in a short time.

Preferably the method according to the invention is used in diagnostics, for diagnostic analysis or for bioanalytics, or for the screening of tissue or fluids from the human or even animal body for the presence of certain methylation pattern. Further, the method according to the invention is used to enhance the speed,  
10 accuracy or sensitivity of the detection of methylation sites in nucleic acids.

In an embodiment of the invention, guanidinium hydrogen sulfite is used for chemically modifying a nucleic acid, preferably wherein a cytosine base in a nucleic acid is converted to an uracil base. In another embodiment of the invention, guanidinium hydrogen sulfite is used to prepare a solution comprising guanidinium and sulfite ions. Preferably, the solution is used for converting a cytosine base in a  
15 nucleic acid to an uracil base.

In another preferred embodiment, the present invention is directed to a kit for performing a bisulfite reaction containing guanidinium hydrogen sulfite or a solution comprising bisulfite ions and guanidinium prepared from guanidinium  
20 hydrogen sulfite. Generally, kits known in the art further comprise plastics ware which may be used during the bisulfite procedure as e.g. microtiter-plates in the 96 or 384 well format or reaction tubes manufactured e.g. by Eppendorf, Hamburg, Germany. Further, additional reagents may be present which contain buffers suitable for use in the present invention, primers, probes, a DNA polymerase,  
25 preferably a thermostable DNA polymerase and possibly nucleotides. Therefore, in an embodiment of the invention a kit is provided comprising guanidinium hydrogen sulfite, primers, probes, a DNA polymerase and nucleotides. Preferably, the kit according to the invention is used for a reaction wherein a cytosine base, preferably cytosine bases, in a nucleic acid is converted to an uracil base, preferably  
30 uracil bases, in the presence of bisulfite ions whereby preferably 5-methyl-cytosine bases are not significantly converted.

The following examples, references and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

## 5 Description of the Figures

Fig. 1: The steps of the bisulfite method

Figs. 2 to 4: HPLC profiles of the reaction mixtures after certain time periods as indicated in the examples

Fig. 2a) 1 M sodium hydrogensulfite, 30 min

10 Fig. 2b) 1 M guanidinium hydrogensulfite, 30 min

Fig. 3a) 2 M sodium hydrogensulfite, 30 min

Fig. 3b) 2M guanidinium hydrogensulfite, 30 min

Fig. 4a) 2 M sodium hydrogensulfite, 60 min

Fig. 4b) 2 M guanidinium hydrogensulfite, 60 min

## 15 Examples

### 1 Production of guanidinium hydrogen sulfite

130 g (722 mmol) of guanidine carbonate (Fluka 50930 ) was dissolved in 700 ml of water at room temperature. A stream of SO<sub>2</sub> was bubbled through this solution for several hours until pH 2-3 was measured. The yellow solution was lyophilised. The  
20 yield of the colorless product was 184 g.

<sup>1</sup>H-NMR ([D<sub>6</sub>]DMSO, 300 MHz): δ = 7.12 (s, 6 H).

<sup>13</sup>C-NMR ([D<sub>6</sub>]DMSO, 75 MHz): δ = 158.3.

Elementary analysis yielded data as expected.

## 2 Desamination reaction with an oligonucleotide

### 2.1.1 Experimental design:

A double stranded nucleic acid formed from two oligonucleotides ("GSTP1 ds") is treated with sodium disulfite or guanidinium hydrogensulfite in different molar concentrations. After this procedure the GSTP1 ds is desulfonated and desalted.  
5 The purified GSTP1 ds is analysed by HPLC (see Fig. 2 to 4). The two oligonucleotides forming the double-stranded nucleic acid ("GSTP1 ds") are described below and have the sequences SEQ ID NO: 1 and 2.

### 2.1.2 Method

#### 10 2.1.2.1 Oligonucleotides

Oligo 1: 5'-GGG ACT CCA GGG CGC CCC TC-3' (SEQ ID NO: 1)

MW = 6079,97Da

1OD = 5,04nmol

Oligo 2: 5'-GAG GGG CGC CCT GGA GTC CC-3' (SEQ ID NO: 2)

15 MW = 6159,99Da

1OD = 4,83nmol

#### 2.1.2.2 Deamination of GSTP1 ds using sodium disulfite:

5 nmol (MW 12239.96 Da) of GSTP1 ds are mixed with 200µl of bisulfite reagent (1-2M, pH 5.5) and incubated for several minutes (30 min - 60 min) at 80 °C.

#### 20 2.1.2.3 Deamination of GSTP1 ds using guanidinium hydrogensulfite:

5 nmol (MW 12239.96 Da) of GSTP1 ds are mixed with 200ul of bisulfite reagent (1-2M, pH 5.5) and incubated for several minutes (30 min - 60 min) at 80 °C.

#### 2.1.2.4 Desulfonation and desalting:

200µl of the deaminated GSTP1 ds are mixed with 500µl of 2N KOH and left for 30  
25 minutes at room temperature. Thereafter a gel filtration with water on Sephadex G-

25M (Pharmacia, Code No. 17-0851-01, Lot. No. QG 11018, bed volume 9ml) takes place. The solvent is removed and the residue dissolved in 200µl of water. 40µl are used for the HPLC.

#### 2.1.2.5 HPLC:

- 5 Column: Dionex DNAPac PA-100SEL, 4x250mm  
with precolumn: Product No. SP3816 Serial No. 0440
- Solvent A: 0.2 M NaCl in 0.01 M NaOH
- Solvent B: 1 M NaCl in 0.01 M NaOH
- Gradient: 0 min : 50 % A/ 50 % B
- 10 25 min: 100 % B, 1 ml/min

- The kinetic of the bisulfite reaction is analysed via HPLC. It is shown that under the same conditions the kinetic of the deamination process is much faster with relative low concentrations (2 M) of guanidinium hydrogensulfite in comparison with the
- 15 standard reagent sodiumhydrogensulfite (see Fig. 2 to 4). This shows clearly at relative low bisulfite concentration the advantages of the chaotropic guanidinium cation over sodium. The chromatogram of the 1 M bisulfite reaction is an example of the status shortly after starting the bulfite reaction. As later the elution the more the deamination reaction is completed.

### 20 3 Establishment of a LC-PCR specific for Bisulphite treated DNA

#### General

- The fact that the bisulfite reaction has worked and converted non-methylated cytosines to uracil can be demonstrated by a polymerase chain reaction whereby primers are used which are specific to a region of the nucleic acid sequence wherein
- 25 non-methylated cytosines have been converted to uracils, i.e. the base adenine in the primer is opposite to the uracil being the bisulfite reaction product from non-methylated cytosines. In case of incomplete conversion, the primer could not hybridize to this region as there would be cytosines not matching the adenine bases in the primer. This would have the effect that no PCR product would be obtained.

An improved method to perform rapid polymerase chain reactions is disclosed e.g. in US 6,174,670 and is used in the LightCycler® instrument (Roche, Mannheim, Germany). In this method, two labeled probes can come into close proximity in an amplificate dependent manner so that the two labels can perform a fluorescence energy transfer (FRET). The amount of the amplificate thereby correlates with the intensity of the emitted light of a certain wavelength. This specific PCR method can therefore be used to analyze whether a complete conversion of non-methylated cytosines was obtained, by e.g. analyzing the promoter region of the glutathion-S-transferase  $\pi$  gene (see e.g. SEQ ID NO: 3 for the full length sequence of this gene and the promoter, US 5,552,277, Genbank accession code M24485 and Morrow, C.S., et al., Gene 75 (1989) 3-11) using suitable probes and primers. However, the expert skilled in the art knows that other methods can be used for this evaluation as well. Fluorescence measurements are normalized by dividing by an initial fluorescence measurement, i.e., the background fluorescence, obtained during a cycle early in the reaction while the fluorescence measurements between cycles appear to be relatively constant. The cycle number chosen for the initial fluorescence measurement is the same for all reactions compared, so that all measurements represent increases relative to the same reaction cycle. In the early cycles of a polymerase chain reaction amplification, the number of target molecules can be described by the geometric equation  $N_i = N_o \times (1 + E)^i$ , where  $N_o$  = the number of target molecules at the start of the reaction,  $N_i$  = the number of target molecules at the completion of the  $i$ -th cycle,  $E$  = the efficiency of the amplification ( $0 \leq E \leq 1$ ). During this geometric growth phase of the amplification, the number of cycles required to reach a particular threshold value ( $C_T$  value or crossing point) is inversely proportional to the logarithm of  $(1 + E)$ . Thus, the  $C_T$  value represents a measure of the reaction efficiency that allows comparisons between reactions. A decrease in the  $C_T$  value, which means that the reaction reached the threshold value in fewer cycles, indicates an increase in reaction efficiency. As the increase in amplification product is monitored by measuring the increase in reaction fluorescence, the  $C_T$  is defined herein as the number of amplification cycles carried out until the fluorescence exceeded an arbitrary fluorescence level (AFL). The AFL was chosen close to the baseline fluorescence level, but above the range of random fluctuations in the measured fluorescence, so that the reaction kinetics were measured during the geometric growth phase of the amplification. Accumulation of amplified product in later cycles inhibits the reaction and eventually leads to a reaction plateau. An AFL of 1.5 was chosen for all



- reactions. Because a PCR amplification consists of discrete cycles and the fluorescence measurements are carried out once per cycle, the measured fluorescence typically increases from below the AFL to above the AFL in a single cycle. To improve the precision of the measurements, an "exact" number of cycles to reach the AFL threshold, referred to herein as the  $C_T$  value or crossing point, was calculated by interpolating fluorescence measurements between cycles.

### General methodology

- The following experiment demonstrates that the described PCR on the LightCycler® instrument can be used as an evaluation tool for bisulfite treated DNA. It shows that the designed primer/probe combination gives positive results only with DNA after bisulfite treatment. Bisulfite treated DNA (in this case bisulfite DNA was treated according to the protocol described in example 2) and untreated DNA were amplified in parallel using the same template concentrations (20ng and 1ng per PCR). PCR analysis on the LightCycler® instrument

#### 3.1.1 Composition of Mastermix:

LC FastStart DNA Master HybridizationProbe 1x, 2mM MgCl<sub>2</sub>, forward Primer 0.5μM, reversed Primer 0.5μM, donor probe 250nM, acceptor probe 250nM, template 10μl, total PCR volume 20μl.

#### 3.1.2 PCR-conditions:

- Denaturation 10min/95°C  
55 cycles    95°C/10s  
                 65°C/10s – signal acquisition  
                 72°C/10s    Ramp time 20°C/s

## 3.1.3 Result

MDNA / PCR	Bisulphite treatment	C <sub>T</sub> -Value or Crossingpoint
20 ng	Yes	30.55
		29.72
		29.95
		30.06
1 ng	yes	34.7
		35.8
		34.07
		33.86
20 ng	No	No growth curve
		No growth curve
		No growth curve
		No growth curve
1 ng	No	No growth curve
		No growth curve
		No growth curve
		No growth curve

- The result shows crossing points only for bisulfite treated DNA. Therefore this PCR is suitable in evaluating bisulfite methods. For those skilled in the art it is clear that
- 5 any PCR might be used as an evaluation tool if it is guaranteed that the primer/probe combination does not react with DNA before bisulfite treatment.

#### 4 Gua-Hydrogen- Sulfite can replace the standard deamination reagent Sodium-Bisulfite during analysis of DNA methylation

##### Experimental design:

- 10 Methylated DNA is spiked in unmethylated DNA, denatured and then treated in parallel with sodium bisulfite or guanidinium hydrogen sulfite. Thereafter, the DNA is desalted using magnetic glass particles, desulfonated and again desalted. The purified DNA is analysed using a real time kinetic PCR protocol that detects only bisulfite treated methylated DNA.

#### 4.1.1 Denaturation of DNA:

100 µl of methylated DNA (Serologicals Corporation, Norcross, GA, USA; Cat S 7821) dilution (50 ng/assay spiked in 1000ng hDNA background, Roche Cat.1691112; 5 replicates per method), and 11 µl 2 M NaOH are mixed and  
5 incubated for 10 min at 37 °C.

#### 4.1.2 Deamination of DNA: Method 1 using standard reagent Sodium-Bisulfite

111 µl of the denatured DNA are mixed with 200 µl bisulfite reagent (2.5M sodium bisulfite =5M sulfite solution, 125 mM hydroquinone, pH 5.5) and incubated for 2  
10 h at 80 °C.

#### 4.1.3 Deamination of DNA: Method 2 using reagent Guanidinium-Hydrogen- Sulfite

111 µl of the denatured DNA are mixed with 200 µl bisulfite reagent (5M guanidinium hydrogen sulfite, pH 5.5) and incubated for 2 h at 80 °C.

#### 15 4.1.4 Processing using MGPs

311 µl of the deaminated DNA are mixed with 600 µl binding buffer (MagNAPure DNA Isolation Kit I, Roche Cat. Nr. 3 003 990) and 75µl magnetic glass particle solution (MagNAPure DNA Isolation Kit I) and incubated for 15min/ room temperature with continuous mixing. Thereafter, the magnetic glass particles are  
20 washed three times with 1ml 70% Ethanol. Bound free separation is done in a magnetic separator (Roche Cat.1641794). Thereafter, desulphonation takes place by adding 250 µl 90% EtOH / 20mM NaOH to the DNA bound to the MGPs; the mixture is incubated for 10min at room temperature with mixing. Thereafter the MGPs are washed two times with 90% Ethanol. To remove ethanol rests the MGPs  
25 are heated for 15min./60°C in a thermomixer with open lid. Thereafter the DNA is eluted with 50µl 10mM Tris/0.1mM EDTA pH 7.5 (15min/ 60°C). 10µl of the eluted DNA is used for subsequent PCR analysis.

**Analysis of deaminated DNA on the LightCycler® instrument****4.1.5 Composition of Mastermix**

LightCycler® FastStart DNA Master HybridizationProbe 1x (Roche 2239272),  
 3mM MgCl<sub>2</sub>, forward Primer 0.4 µM, reversed Primer 0.4 µM, donor probe 200  
 5 nM, acceptor probe 200 nM, template 10 µl, total PCR volume 20 µl.

**4.1.6 PCR-conditions**

Denaturation 10min/95°C  
 55 cycles    95°C/10s  
                  62°C/10s – signal acquisition  
 10               72°C/10s                      Ramp time 20°C/s

**Results:**

replicates	Methylated DNA/PCR	Sodium bisulfite reagent	Guanidinium hydrogensulfite reagent
		C <sub>T</sub> -Values or Crossing points	
1	10ng	30.24	29.22
2	10ng	29.68	29.85
3	10ng	30.20	29.64
4	10ng	29.89	29.74
5	10ng	29.81	29.18
<i>Mean value</i>		<i>29.96</i>	<i>29.53</i>

The C<sub>T</sub>-values or crossing points calculated during real time PCR are almost  
 identical for both sulfite reagents used, for guanidinium hydrogensulfite the mean  
 15 value is even lower; i.e. that guanidinium hydrogensulfite can replace the standard  
 deamination reagent showing a somewhat better performance.

## **5 Use of guanidinium hydrogen sulfite without prior denaturation of DNA for methylation analysis**

### **Experimental design:**

- Methylated DNA is spiked in unmethylated DNA, denatured or not denatured and
- 5 then treated in parallel with sodium bisulfite or guanidinium hydrogen sulfite. Thereafter, the DNA is desalted using magnetic glass particles, desulfonated and again desalted. The purified DNA is analysed using a real time kinetic PCR protocol that detects only bisulfite treated methylated DNA.

#### **5.1.1 Denaturation of DNA:**

- 10 100 µl of methylated DNA (Serologicals Corporation, Norcross, GA, USA; Cat S 7821) dilution (50 ng/assay spiked in 1000ng hDNA background, Roche Cat.1691112; 4 replicates per method), and 11 µl 2 M NaOH are mixed and incubated for 10 min at 37 °C.

#### **5.1.2 Deamination of DNA: Method 1 using standard reagent Sodium-Bisulfite**

- 15 111 µl of the denatured DNA or 100µl of not denatured DNA are mixed with 200 µl bisulfite reagent (2.5M sodium bisulfite, 125 mM hydroquinone, pH 5.5) and incubated for 2 h at 80 °C.

#### **5.1.3 Deamination of DNA: Method 2 using reagent Guanidinium-Hydrogen-Sulfite**

- 20 111 µl of the denatured DNA or 100µl of not denatured DNA are mixed with 200 µl bisulfite reagent (5M guanidinium hydrogen sulfite, pH 5.5) and incubated for 2 h at 80 °C.

#### **5.1.4 Processing using MGPs**

- 311 µl of the deaminated DNA are mixed with 600 µl binding buffer (MagNAPure
- 25 DNA Isolation Kit I, Roche Cat. Nr. 3 003 990) and 75µl magnetic glass particle solution (MagNAPure DNA Isolation Kit I) and incubated for 15 min/ room

- temperature with continuous mixing. Thereafter, the magnetic glass particles are washed three times with 1ml 70% Ethanol. Bound free separation is done in a magnetic separator (Roche Cat.1641794). Thereafter, desulphonation takes place by adding 250 µl 90% EtOH / 20mM NaOH to the DNA bound to the MGPs; the
- 5 mixture is incubated for 10min at room temperature with mixing. Thereafter the MGPs are washed two times with 90% Ethanol. To remove residual ethanol the MGPs are heated for 15min/60°C in a thermomixer with open lid. Thereafter the DNA is eluted with 50µl 10mM Tris/0.1mM EDTA pH 7.5 (15min./60°C). 10µl of the eluted DNA is used for subsequent PCR analysis.

10 Analysis of deaminated treated DNA on the LightCycler® instrument

5.1.5 Composition of Mastermix

LightCycler® FastStart DNA Master HybridizationProbe 1x (Roche 2239272), 3mM MgCl<sub>2</sub>, forward Primer 0.4 µM, reversed Primer 0.4 µM, donor probe 200 nM, acceptor probe 200 nM, template 10 µl, total PCR volume 20 µl.

15 5.1.6 PCR-conditions

Denaturation 10min/95°C

55 cycles 95°C/10s

62°C/10s – signal acquisition

72°C/10s

Ramp time 20°C/s

**Results:**

replicates	Methylated DNA/PCR	Sodium disulfite reagent With denaturation	Guanidinium hydrogensulfite reagent With denaturation	Sodium disulfite reagent Without denaturation	Guanidinium hydrogensulfite reagent Without denaturation
<b>C<sub>T</sub> Values or Crossing points</b>					
1	10ng	29.74	29.06	34.35	33.62
2	10ng	29.48	29.85	35.17	33.92
3	10ng	29.66	29.86	33.64	33.60
4	10ng	29.80	29.86	33.10	33.63
<i>Mean value</i>		<i>29.67</i>	<i>29.66</i>	<i>34.07</i>	<i>33.69</i>

The result shows that the Bisulfite reaction does work without prior denaturation of DNA; the novel reagent guanidinium hydrogen sulfite is more efficient because the median of the crossing points is lower than that of the standard bisulfite reagent.

**6 Guanidinium Hydrogensulfite can be used in lower molar concentrations for methylation analysis**

**Experimental design:**

Methylated DNA is spiked in unmethylated DNA, denatured and then treated in parallel with sodium disulfite or guanidinium hydrogen sulfite in different molar concentrations. Thereafter, the DNA is desalted using magnetic glass particles, desulfonated and again desalted. The purified DNA is analysed using a real time kinetic PCR protocol that detects only bisulfite treated methylated DNA.

**6.1.1 Denaturation of DNA:**

100 µl of methylated DNA (Serologicals Corporation, Norcross, GA, USA; Cat S 7821) dilution (50 ng/assay spiked in 1000ng hDNA background, Roche

Cat.1691112; 4 replicates per method), and 11 µl 2 M NaOH are mixed and incubated for 10 min at 37 ° C.

#### 6.1.2 Deamination of DNA: Method 1 using standard reagent Sodium-Bisulfite

111 µl of the denatured DNA or 100µl of not denatured DNA are mixed with 200  
5 µl bisulfite reagent (2.5M – 1.5M – 0.5M sodium disulfite, 125 mM hydroquinone, pH 5.5) and incubated for 2 h at 80 °C. (Comment: a 2.5M solution of sodium disulfite is 5M regarding sulfite ions)

#### 6.1.3 Deamination of DNA: Method 2 using reagent Guanidinium-Hydrogen-Sulfite

10 111 µl of the denatured DNA or 100µl of not denatured DNA are mixed with 200 µl bisulfite reagent (5M – 3M – 1M guanidinium hydrogen sulfite, pH 5.5) and incubated for 2 h at 80 °C.

#### 6.1.4 Processing using MGPs

311 µl of the deaminated DNA are mixed with 600 µl binding buffer (MagNAPure  
15 DNA Isolation Kit I, Roche Cat. Nr. 3 003 990) and 75µl magnetic glass particle solution (MagNAPure DNA Isolation Kit I) and incubated for 15min/ room temperature with continuous mixing. Thereafter, the magnetic glass particles are washed three times with 1ml 70% Ethanol. Bound free separation is done in a magnetic separator (Roche Cat.1641794). Thereafter, desulphonation takes place by  
20 adding 250 µl 90% EtOH / 20mM NaOH to the DNA bound to the MGPs; the mixture is incubated for 10min at room temperature with mixing. Thereafter the MGPs are washed two times with 90% Ethanol. To get rid of ethanol rests the MGPs were heated for 15min./60°C in a thermomixer with open lid. Thereafter the DNA is eluted with 50µl 10mM Tris/0.1mM EDTA pH 7.5 (15min./60°C). 10µl of  
25 the eluted DNA is used for subsequent PCR analysis.



**Analysis of deaminated treated DNA on the LightCycler® instrument****6.1.5 Composition of Mastermix**

LightCycler® FastStart DNA Master HybridizationProbe 1x (Roche 2239272),  
3mM MgCl<sub>2</sub>, forward Primer 0.4 µM, reversed Primer 0.4 µM, donor probe 200  
5 nM, acceptor probe 200 nM, template 10 µl, total PCR volume 20 µl.

**6.1.6 PCR-conditions**

Denaturation 10min/95°C

55 cycles 95°C/10s

62°C/10s – signal acquisition

10 72°C/10s Ramp time 20°C/s

**Results:**

Replicates	Methylated DNA/PCR	Amount of sulfite during deamination reaction	Sodium disulfite reagent	Guanidinium hydrogensulfite reagent
			<b>C<sub>T</sub> Values or Crossing points</b>	
1	10ng	5M	29.24	28.56
2	10ng	5M	29.36	29.35
3	10ng	5M	29.19	28.87
4	10ng	5M	29.61	28.94
<i>Mean value</i>			<b>29.35</b>	<b>28.93</b>
1	10ng	3M	30.67	29.76
2	10ng	3M	30.20	29.68
3	10ng	3M	30.61	30.59
	10ng	3M	31.10	30.53
<i>Mean value</i>			<b>30.65</b>	<b>30.14</b>
1	10ng	1M	-	-
2	10ng	1M	-	-
3	10ng	1M	-	-
4	10ng	1M	41.64	-
<i>Mean value</i>				

The results show that desamination is also possible with a lower molar concentration of sulfite ions, but the sensitivity drops; a concentration of 1M is too low. The novel reagent is somewhat more efficient because the difference in crossing points between 5M and 3M is 1.21, whereas for the standard reagent it is 1.3.

**7 GuaSulfit can be used for solid phase deamination in DNA methylation analysis**

**10 Experimental design**

Methylated DNA is spiked in unmethylated DNA, denatured in solution and transferred to silica solid phase (column). Deamination is done in parallel with

sodium disulfite or guanidinium hydrogen sulfite. Thereafter the DNA is desalted, desulfonated and again desalted. The purified DNA is analysed using a real time kinetic PCR protocol that detects only bisulfite treated methylated DNA.

#### 7.1.1 Denaturation of DNA:

- 5 100 µl of methylated DNA (Serologicals Corporation, Norcross, GA, USA; Cat S 7821) dilution (50 ng/assay spiked in 1000ng hDNA background, Roche Cat.1691112; 3 replicates per method), and 11 µl 2 M NaOH are mixed and incubated for 15 min at 37 ° C.

#### 7.1.2 Solid Phase Deamination of DNA: Method 1 using standard reagent

##### 10 Sodium-Bisulfite

111 µl of the denatured DNA are mixed with 300 µl bisulfite reagent (2,5M sodium bisulfite = 5M sulfite in solution, pH 5.5) and 100µl ethanol and loaded on to a silica column (from High Pure Template Preparation Kit, Roche, 1796828); incubation is overnight at 50°C.

#### 15 7.1.3 Solid Phase Deamination of DNA: Method 2 using reagent Guanidinium-Hydrogen- Sulfite

- 111 µl of the denatured DNA are mixed with 300 µl bisulfite reagent (5M guanidinium hydrogensulfite, pH 5.5) and 100µl ethanol and loaded on to a silica column (from High Pure Template Preparation Kit, Roche, 1796828); incubation is  
20 overnight at 50°C.

#### 7.1.4 Processing on silica columns

- After overnight incubation columns are centrifuged 1min/8000rpm (Eppendorf bench top centrifuge) and two times washed with 500µl 70% ethanol. Desulfonation is performed by adding 500µl reagent (38% ethanol/100mM  
25 EDTA/200mM NaOH) and incubation for 20min. at room temperature. After short centrifugation the columns are washed twice with 500µl 90% ethanol each. To remove the entire ethanol the columns are centrifuged for 20sec at 14000rpm. Bound DNA is eluted by adding 100µl prewarmed (70°C) PCR grade water. The

columns are centrifuged again and the supernatant is used for subsequent PCR analysis.

#### Analysis of deaminated treated DNA on the LightCycler® instrument

##### 7.1.5 Composition of Mastermix

- 5 LightCycler® FastStart DNA Master HybridizationProbe 1x (Roche 2239272), 3mM MgCl<sub>2</sub>, forward Primer 0.4 µM, reversed Primer 0.4 µM, donor probe 200 nM, acceptor probe 200 nM, template 10 µl, total PCR volume 20 µl.

##### 7.1.6 PCR-conditions

Denaturation 10min/95°C

- 10 55 cycles      95°C/10s  
                     62°C/10s – signal acquisition  
                     72°C/10s                      Ramp time 20°C/s

#### Results:

Replicates	Solid phase desamination with Sodium disulfite reagent	Solid phase desamination with Guanidinium hydrogensulfite reagent
	C <sub>T</sub> -Values or Crossing points	
1	32.72	31.68
2	32.85	31.64
3	32.47	31.75
<i>Mean value</i>	<i>32.68</i>	<i>31.69</i>

- 15 The results show that solid phase desamination is possible with both sulfite reagents, but the efficiency for the novel reagent is significantly higher: the resulting crossing points are 1 cycle earlier corresponding to a twofold better yield of bisulfite treated DNA.

## 8 GuaSulfit can be used for combined process SP + BIS

### Experimental design

A clinical sample is directly contacted with the bisulfite reagent (GuaSulfit or Na-Bisulfit) without prior purification of the DNA. After incubation the processing of  
5 the converted DNA is done using the magnetic glass particles as usual. The purified DNA is analysed using a real time kinetic PCR protocol that detects only bisulfite treated DNA.

#### 8.1.1 Combined SP and BIS process:

200µl of normal human serum or normal human serum spiked with 0.2µg of  
10 nucleosomal DNA (3 replicates each) are mixed with 50µl Proteinase K (Roche) and 600µl BIS reagent (either 6M Guanidiniumhydrogen -Sulfit or 5M Sodiumbisulfite); pH is adjusted to 5.5 with 5M NaOH. Then the mixture is incubated for 2h at 80°C in a thermomixer.

#### 8.1.2 Processing using MGPs

15 Thereafter 6mg magnetic glass particles ((MagNAPure DNA Isolation Kit I, Roche Cat. Nr. 3 003 990) in 600µl isopropanol are added, and the solution is mixed thoroughly and incubated for 15min/ room temperature with continuous mixing. Thereafter, the magnetic glass particles are washed three times with 1ml 70% Ethanol. Bound free separation is done in a magnetic separator (Roche  
20 Cat.1641794). Thereafter, desulphonation takes place by adding 250 µl 90% EtOH / 20mM NaOH to the DNA bound to the MGPs; the mixture is incubated for 10min at room temperature with mixing. Thereafter the MGPs are washed two times with 90% Ethanol. To get rid of ethanol rests the MGPs were heated for 15min./60°C in a thermomixer with open lid. Thereafter the DNA is eluted with 50µl 10mM  
25 Tris/0.1mM EDTA pH 7.5 (15min./60°C). 10µl of the eluted DNA is used for subsequent PCR analysis.

**Analysis of deaminated treated DNA on the LightCycler® instrument****8.1.3 Composition of Mastermix**

LightCycler® FastStart DNA Master HybridizationProbe 1x (Roche 2239272),  
 2mM MgCl<sub>2</sub>, forward Primer 0.5 µM, reversed Primer 0.5 µM, donor probe 300  
 5 nM, acceptor probe 300 nM, template 10 µl, total PCR volume 20 µl.

**8.1.4 PCR-conditions**

Denaturation 10min/95°C

55 cycles 95°C/10s

62°C/10s – signal acquisition

10 72°C/10s Ramp time 20°C/s

**Results:**

Sample	Sodium disulfite reagent	Guanidinium hydrogensulfite reagent
	<b>C<sub>T</sub>-Values or Crossing points</b>	
NS	No growth curve	43.04
NS	No growth curve	37.67
NS	No growth curve	40.96
<i>Mean value</i>	-	<i>40.56</i>
NS + DNA	36.75	35.37
NS + DNA	37.56	34.40
NS + DNA	37.55	36.26
<i>Mean value</i>	<i>37.29</i>	<i>35.34</i>

The results show that the new format “combination of Sample preparation and  
 BIS-Treatment” results in converted, amplifiable DNA. For the standard BIS  
 15 reagent positive results are seen only for the spiked samples; that means that the  
 overall efficiency of the process is still quite limited. In contrast however using the

novel BIS reagent results in positive results for the unspiked serum as well as the spiked serum, indicating that the novel BIS reagent can be used more efficiently for the combined SP-BIS format than the standard reagent.

9 GuaSulfit can be used as Binding reagent for DNA isolation on silica surfaces

5 Experimental design

50ng human genomic DNA, Roche 1691112 is spiked in 200µl normal negative serum. Then the DNA is isolated using the High Pure Template preparation kit (Roche 1796828) either with the recommended binding buffer or with 5M Guanidinium hydrogensulfit pH 5.5 or 5M Sodium Bisulfite pH 5.5 as binding  
10 buffer (3 replicates each). The purified DNA is then quantified in a real time kinetic PCR using the LC Control Kit (Roche 2015102) that detects  $\beta$  Globin DNA.

Results

Replicates	Original Binding Buffer		5M Sodium Bisulfite as Binding buffer		5M Guanidinium Hydrogensulfit as Binding buffer	
	cp	ng DNA	cp	ng DNA	cp	ng DNA
1	26.6	50.2	28.97	9.56	29.61	6.11
2	26.59	50.4	28.72	11.4	29.36	7.32
3	26.74	45.6	28.95	9.74	29.56	6.34
Mean value	26.64	48.7	28.88	10.2	29.51	6.6

15 The results show that the original binding buffer in the kit gives the best performance, but both sulfite reagents might be used also as binding buffers; the

novel reagent is somewhat less efficient and some more optimization might be needed.



List of References

- Abramson, R.D., and Myers, T.W., Curr. Opin. Biotechnol. 4 (1993) 41-47
- Alderton, R.P., et al., Anal. Biochem. 201 (1992) 166-169
- Ausubel, F., et al., in "Current protocols in molecular biology" (1994), Eds. F. Ausubel, R. Brent and K. R.E., Wiley & Sons Verlag, New York
- 5 Barany, F., PCR Methods Appl. 1 (1991) 5-16
- Barany, F., Proc. Natl. Acad. Sci. USA 88 (1991) 189-193
- Benyajati, C., et al., Nucleic Acids Res. 8 (1980) 5649-5667
- Braunauer, in "The Adsorption of Gases and Vapors" (1943), Princeton University Press
- 10 Clark, S.J., et al., Nucleic Acids Res. 22 (1994) 2990-2997
- DE 3724442
- EP 0 200 362
- EP 0 201 184
- 15 EP 0 389 063
- EP 0 439 182
- Feil, R., et al., Nucleic Acids Res. 22 (1994) 695-696
- Frommer, M., et al., Proc. Natl. Acad. Sci. U S A 89 (1992) 1827-1831
- GB 91/00212
- 20 Grigg, G., and Clark, S., Bioessays 16 (1994) 431-436
- Grigg, G.W., DNA Seq. 6 (1996) 189-198
- Grunau, C., et al., Nucleic Acids Res. 29 (2001) E65-5
- Guatelli, J.C., et al., Proc. Natl. Acad. Sci. USA 87 (1990) 1874-1878
- Jakobi, R., et al., Anal. Biochem. 175 (1988) 196-201
- 25 Komiyama, M., and Oshima, S., Tetrahedron Letters 35 (1994) 8185-8188
- Kwoh, D.Y., et al., Proc. Natl. Acad. Sci. USA 86 (1989) 1173-1177
- Lottspeich, and Zorbas, in "Bioanalytik" (1998), Eds. L. a. Zorbas, Spektrum Akademischer Verlag, Heidelberg, Berlin, Germany
- Marko, M.A., et al., Anal. Biochem. 121 (1982) 382-387
- 30 Morrow, C.S., et al., Gene 75 (1989) 3-11
- Oakeley, E.J., Pharmacol. Ther. 84 (1999) 389-400
- Olek, A., et al., Nucleic Acids Res. 24 (1996) 5064-5066
- Paulin, R., et al., Nucleic Acids Res. 26 (1998) 5009-5010
- Raizis, A.M., et al., Anal. Biochem. 226 (1995) 161-166

- Sambrook, J., et al., in "Molecular Cloning: A Laboratory Manual" (1989), Eds. J. Sambrook, E. F. Fritsch and T. Maniatis, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY
- Spray Drying Handbook (1991), John Wiley & Sons, New York
- 5 US 4,683,202  
US 5,130,238  
US 5,137,806  
US 5,210,015  
US 5,234,809
- 10 US 5,487,972  
US 5,552,277  
US 5,595,890  
US 5,639,611  
US 5,786,146
- 15 US 5,804,375  
US 6,174,670  
US 6,331,393
- Vogelstein, B., and Gillespie, D., Proc. Natl. Acad. Sci. USA 76 (1979) 615-619
- Warnecke, P.M., et al., Methods 27 (2002) 101-107
- 20 Whelen, A.C., and Persing, D.H., Annu. Rev. Microbiol. 50 (1996) 349-373  
WO 00/32762  
WO 00/37291  
WO 01/37291  
WO 01/98528
- 25 WO 02/31186  
WO 90/01069  
WO 90/06045  
WO 92/02638  
WO 92/0880A
- 30 WO 96/41811  
WO 99/16781  
WO 99/40098
- Wu, D.Y., and Wallace, R.B., Genomics 4 (1989) 560-569

Patent Claims

1. Method for the conversion of a cytosine base in a nucleic acid to an uracil base comprising the steps of
  - a) providing a solution that contains a nucleic acid,
  - 5 b) providing guanidinium hydrogen sulfite and preparing a solution comprising guanidinium and sulfite ions,
  - c) mixing the solutions from step a) and b)
  - d) incubating the solution obtained in step c) containing the nucleic acid and guanidinium and sulfite ions whereby the nucleic acid is  
10 deaminated,
  - e) incubating the deaminated nucleic acid under alkaline conditions whereby the deaminated nucleic acid is desulfonated,
  - f) isolating the deaminated nucleic acid.
- 15 2. The method according to claim 1, characterized in that the concentration of guanidinium ions and sulfite ions is 0.1 to 8 M, preferably 2 to 8 M.
3. The method according to any of the claims 1 to 2, characterized in that the pH of the solutions in step b) and c) is in the acidic range, preferably between 4.5 to 6.5.
- 20 4. The method according to any of the claims 1 to 3, characterized in that the incubation temperature in step d) and e) is between 0 °C to 90 °C, preferably between 18 °C to 90 °C.
5. The method according to any of the claims 1 to 4, characterized in that the incubation time in step d) is between 30 min to 48 hours, preferably 24 hours.
- 25 6. The method according to any of the claims 1 to 5, characterized in that the step e) is performed by adding an alkaline solution or buffer, preferably a solution containing a hydroxide, preferably sodium hydroxide, or a solution containing ethanol, sodium chloride and sodium hydroxide, preferably a solution containing 38% (volume/volume) ethanol, 100 mM NaCl, 200 mM  
30 NaOH.

7. The method according to any of the claims 1 to 6, characterized in that the incubation temperature in step e) is between 0 °C to 90 °C, preferably between 18 °C to 90 °C.
8. The method according to any of the claims 1 to 7, characterized in that the incubation time in step e) is between 5 min to 60 min.
9. Use of guanidinium hydrogen sulfite for chemically modifying a nucleic acid.
10. Use according to claim 9 wherein a cytosine base in a nucleic acid is converted to an uracil base.
11. Use of guanidinium hydrogen sulfite to prepare a solution comprising guanidinium and sulfite ions.
12. Use according to claim 1 wherein the solution is used for converting a cytosine base in a nucleic acid to an uracil base.
13. A kit containing guanidinium hydrogen sulfite.
14. Use of the kit according to claim 13 for a reaction wherein a cytosine base in a nucleic acid is converted to an uracil base in the presence of bisulfite ions.

Fig. 1

Fig. 1

Reaction of cytosines in nucleic acids with bisulfite




Fig. 2 a)




Fig. 2 b)




Fig. 3 a)




Fig. 3 b)




Fig. 4 a)





Fig. 4 b)





## SEQUENCE LISTING

<110> Roche Diagnostics GmbH  
F. Hoffmann-La Roche AG

<120> Improved method for bisulfite treatment

<130> 22307 WO

<150> EP 03027754  
<151> 2003-12-02

<160> 3

<170> PatentIn version 3.2

<210> 1  
<211> 20  
<212> DNA  
<213> Homo sapiens

<400> 1  
gggactccag ggcgccctc 20

<210> 2  
<211> 20  
<212> DNA  
<213> Homo sapiens

<400> 2  
gaggggcgcc ctggagtc 20

<210> 3  
<211> 4261  
<212> DNA  
<213> Homo sapiens

<300>  
<301> Morrow et al.  
<302> Structure of the human genomic glutathion S-transferase pi gene  
<303> Genes and Development  
<304> 75  
<306> 3-11  
<307> 1989-01-01

<300>  
<308> M24485  
<309> 2000-03-04  
<313> (1)..(4261)

<300>  
<302> Genetic Diagnosis of Prostate cancer  
<310> US5,552,277  
<311> 1994-07-19

<312> 1996-09-03  
<313> (1)..(4261)

<220>  
<221> misc\_signal  
<222> (1156)..(1162)  
<223> transcription regulatory motif; putative

<220>  
<221> GC\_signal  
<222> (1169)..(1174)

<220>  
<221> GC\_signal  
<222> (1179)..(1184)

<220>  
<221> GC\_signal  
<222> (1194)..(1198)

<220>  
<221> GC\_signal  
<222> (1225)..(1254)

<220>  
<221> GC\_signal  
<222> (4041)..(4046)

<400> 3  
aacaagagat caatatctag aataaatgga gatctgcaaa tcaacagaaa gtaggcagca 60  
aagccaaaga aaatagccta aggcacagcc actaaaagga acgtgatcat gtcctttgca 120  
gggacatggg tggagctgga agccgttagc ctacgcaaac tcacacagga acagaaaacc 180  
agcgagaccg catggtctca cttataagtg ggagctgaac aatgagaaca catggtcaca 240  
tggcggcgat caacacacac tggcgcctgt tgagcggggt gctggggagg gagagtacca 300  
ggaagaatag ctaagggata ctgggcttaa tacctgggtg atgggatgat ctgtacagca 360  
aaccatcatg gcgcacacac ctatgtaaca aacctgcaca tcctgcacat gtaccccaga 420  
acttcaaata aaagttggac ggccaggcgt ggtgggtcac gcctgtaatc ccagcacttt 480  
gggaagccga ggcgtgcaga tcacctaagg tcaggagttc gagaccagcc cggccaacat 540  
ggtgaaaccc cgtctctact aaaaatacaa aaatcagcca gatgtggcac gcacctataa 600  
ttccacctac tcgggaggct gaagcagaat tgcttgaacc cgagaggcgg aggttgcagt 660  
gagccgccga gatcgcgcca ctgcactcca gcctgggcca cagcgtgaga ctacgtcata 720  
aaataaaata aaataacaca aaataaaata aaataaaata aaataaaata aaataataaa 780

ataaaataaa ataaaataaa ataaaataaa ataaagcaat ttcctttcct ctaagcggcc 840  
tccacccctc tcCctgccc tgtgaagcgg gtgtgcaagc tccgggatcg cagcgggtctt 900  
agggaatttc ccccgcgat gtcccggcgc gccagttcgc tgcgcacact tcgctgcggt 960  
cctcttcctg ctgtctgttt actccctagg ccccgctggg gacctgggaa agagggaaaag 1020  
gcttccccgg ccagctgcgc ggcgactccg gggactccag ggcgccctc tgcggccgac 1080  
gcccggggtg cagcggccgc cggggctggg gccggcggga gtccgcggga ccctccagaa 1140  
gagcggccgg cgCcgtagt cagcactggg gcggagcggg gcgggaccac ccttataagg 1200  
ctcggaggcc gcgaggcctt cgctggagtt tcgccccgc agtcttcgcc accagttagt 1260  
acgcgcggcc cgCtccccgg ggatggggct cagagctccc agcatggggc caaccgcgag 1320  
catcaggccc gggctccccg cagggctcct cgcccacctc gagaccggg acgggggcct 1380  
aggggaccca ggacgtcccc agtgccgtta gcggctttca gggggcccg agcgcctcgg 1440  
ggagggatgg gaCcccgggg gcggggaggg ggggcaggct gcgctcaccg cgccttggca 1500  
tcctcccccg ggCtccagca aacttttctt tgttcgctgc agtgccgcc tacaccgtgg 1560  
tctatttccc agTtcgaggt aggagcatgt gtctggcagg gaagggaggc aggggctggg 1620  
gctgcagccc acagcccctc gccaccccg agagatccga acccccttat ccctccgtcg 1680  
tgtggctttt accccgggcc tccttctgt tccccgcctc tcccccatg cctgctcccc 1740  
gccccagtgt tgtgtgaaat cttcggagga acctgtttac ctgttccctc cctgcactcc 1800  
tgacccctcc ccgggttgct gcgaggcggg gtcggcccg tccccacatc tcgtacttct 1860  
ccctccccgc aggcgcgtgc gcggccctgc gcagtctgct ggcagatcag ggccagagct 1920  
ggaaggagga ggtggtgacc gtggagacgt ggcaggaggg ctactcaaa gcctcctgcg 1980  
taagtgacca tgCccgggca aggggagggg gtgctgggcc ttagggggct gtgactagga 2040  
tcgggggacg ccCaagctca gtgccctcc ctgagccatg cctccccaa cagctatacg 2100  
ggcagctccc caagttccag gacggagacc tcaccctgta ccagtccaat accatcctgc 2160  
gtcacctggg ccgcaccctt ggtgagtctt gaacctccaa gtccaggga gccatgggca 2220  
agcctctgcc ccCggagccc ttttgtttaa atcagctgcc ccgcagccct ctggagtggg 2280  
ggaaactgag acCactgag gttacgtagt ttgcccaagg tcaagcctgg gtgcctgcaa 2340  
tccttgccct gtgccaggct gcctcccagg tgtcagggtga gctctgagca cctgctgtgt 2400  
ggcagtctct catccttcca cgcacatcct cttccccctc tcccaggctg gggctcacag 2460

acagccccct gggtggccca tccccagtga ctgtgtgttg atcaggcgcc cagtcacgcg 2520  
gcctgctccc ctccacccaa ccccagggct ctatgggaag gaccagcagg aggcagccct 2580  
ggtggacatg gtgaatgacg gcgtggagga cctccgctgc aaatacatct ccctcatcta 2640  
caccaactat gtgagcatct gcaccagggc tgggcactgg gggctgaaca aagaaagggg 2700  
cttcttgtgc cctcaccccc cttacccttc aggtggcttg ggctgacccc ttcttgggtc 2760  
aggggtgcagg ggctgggtca gctctgggcc agggggccag gggcctggga caagacacaa 2820  
cctgcaccct tattgcctgg gacatcaacc agccaagtaa cgggtcatgg gggcgagtgc 2880  
aaggacagag acctccagca actgggtggtt tctgatctcc tggggtggcg agggcttcct 2940  
ggagtagcca gaggtggagg aggatttgtc gccagtttct ggatggaggt gctggcactt 3000  
ttagctgagg aaaatatgca gacacagagc acatttgggg acctgggacc agttcagcag 3060  
aggcagcgtg tgtgcgcgtg cgtgtgcgtg tgtgtgcgtg tgtgtgtgta cgcttgcatc 3120  
tgtgtcgggt gggttaaggag atagagatgg gcgggcagta ggcccaggtc ccgaaggcct 3180  
tgaaccact gggttgaggt ctctaaggc caatgggggc cattgagaag tctgaacagg 3240  
gctgtgtctg aatgtgaggt ctagaaggat cctccagaga agccagctct aaagcttttg 3300  
caatcatctg gtgagagaac ccagcaagga tggacaggca gaatggaata gagatgagtt 3360  
ggcagctgaa gtggacagga tttgttacta gcctgggtgt ggggagcaag cagaggagaa 3420  
tctgggactc tgggtgtctg cctggggcag acgggggtgt ctcaggggct gggagggatg 3480  
agagtaggat gatacatggt ggtgtctggc aggagggcgg caaggatgac tatgtgaagg 3540  
cactgcccgg gcaactgaag ccttttgaga ccctgctgtc ccagaaccag ggaggcaaga 3600  
ccttcattgt gggagaccag gtgagcatct ggccccatgc tgttccttcc tcgccaccct 3660  
ctgcttccag atggacacag gtgtgagcca tttgttttagc aaagcagagc agacctaggg 3720  
gatgggctta ggccctctgc cccaattcc tccagcctgc tcccgctggc tgagtcctta 3780  
gccccctgc cctgcagatc tccttcgctg actacaacct gctggacttg ctgctgatcc 3840  
atgaggtcct agcccctggc tgcctggatg cgttccccct gctctcagca tatgtggggc 3900  
gcctcagtgc ccggcccaag ctcaaggcct tcctggcctc ccctgagtac gtgaacctcc 3960  
ccatcaatgg caacgggaaa cagtgagggc tggggggact ctgagcggga ggcagagttt 4020  
gccttccttt ctccaggacc aataaaattt ctaagagagc tactatgagc actgtgtttc 4080  
ctgggacggg gcttaggggt tctcagcctc gaggtcgggt ggagggcaga gcagaggact 4140

agaaaacagc tcctccagca cagtcagtgg ctctctggag ccctcagcct ggctgtgttt 4200

actgaacctc acaaactaga agaggaagaa aaaaaaagag agagagaaac aaagagaaat 4260

a 4261

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/013627

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12Q1/68 C07H21/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07H C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 100 50 942 A1 (EPIGENOMICS AG) 18 April 2002 (2002-04-18) example 1 -----	1-14



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

22 February 2005

Date of mailing of the international search report

02/03/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Bardili, W

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/013627

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 10050942	A1	18-04-2002	AU 1812902 A	22-04-2002
			CA 2425366 A1	18-04-2002
			WO 0231186 A2	18-04-2002
			EP 1325154 A2	09-07-2003
			JP 2004511235 T	15-04-2004